| Ytd | -10.66% | |
| 1y | -31.57% |
| Open | 3.11 | Prev Close | 3.12 | Low | 3.06 | High | 3.16 | Mkt Cap | 563.53M |
| Vol | 609.66K | Avg Vol | 3.23M | EPS | -1.23 | P/E | -2.54 | Forward P/E | -3.96 |
| Beta | 2.26 | Short Ratio | 5.85 | Inst. Own | 44.38% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 3.29 | 200-d Avg | 3.84 | 1yr Est | 6.50 |
PRME News
Amova Asset Management Americas Inc. lessened its position in Prime Medicine, Inc. (NASDAQ: PRME) by
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing cont
Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dis
Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its A
U.S. stocks fell, Nasdaq down 100 points. Penguin Solutions Inc (PENG) rose 18.8% after better-than-
-- Arbitration tribunal declared that PM647 is within Prime Medicine’s "Field", confirming P
-- Arbitration tribunal declared that PM647 is within Prime Medicine's “Field”, confirming Prime Med
Dow Jones gains 350 points, Iridium acquired by Rocket Lab for $8B, big stocks recording gains: Quid
Top Wall Street analysts upgraded Prime Medicine, Inc and Casey's General Stores Inc, and upgrad
HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ:PRME) from Neutral to B
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of
-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577
Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead
Prime Medicine's PM359 data gives the stock some early human validation for its main value driver: P
MONTREAL, June 12, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Com
Prime Medicine, Inc. (PRME) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026
Prime Medicine, Inc. (PRME) Presents at Jefferies Global Healthcare Conference 2026 Transcript
CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechno
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnol
Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.28 per share versus the Zacks Conse
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.28) per share which missed the analyst
CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnol
CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechn
MONTRÉAL, April 14, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Co
Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) a
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) a
Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Rep
Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Ou
LifeSci Capital initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and an
On Tuesday, 647 companies set new 52-week lows.
On Monday, 369 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.